Double-Barreled attack: chemo plus targeted liver beads tested for stubborn colon cancer spread
NCT ID NCT04595266
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding a liver-directed chemoembolization procedure to standard chemotherapy can better shrink tumors in people with colorectal cancer that has spread only to the liver and has a poor outlook. About 48 participants will receive either chemotherapy alone or chemotherapy plus tiny beads loaded with irinotecan that are infused directly into the liver's blood supply. The main goal is to see if the combination leads to more tumor shrinkage at 6 months, with hopes of improving survival and enabling liver surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FOLFOX chemotherapy plus a monoclonal antibody (anti-EGFR or bevacizumab), with or without irinotecan-loaded microspheres delivered directly to the liver via chemoembolization
What this could lead to
If this works, it could offer a more effective way to control colorectal cancer that has spread only to the liver, potentially shrinking tumors enough for surgery and extending survival.
What could go wrong
This is a small, early-phase (phase 2) trial with only 48 participants, so results may not apply to everyone. Adding liver chemoembolization also carries risks like liver damage, infection, or side effects from the extra chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER METASTASIS COLON CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Complejo Hospitalario de Navarra
Pamplona, Pamplona, Spain
-
H. Univ. Ramón y Cajal
Madrid, Madrid, 28044, Spain
-
Hospital Clínic
Barcelona, Barcelona, Spain
-
Hospital Parc Taulí
Sabadell, Barcelona, Spain
-
Hospital Universitari i Politècnic La Fe
Valencia, Valencia, 46026, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain
-
Hospital Universitario La Paz
Madrid, Madrid, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, Spain